Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine

Drug and Alcohol Dependence

Volumn 118, Issue 2-3, 2011, Pages 500-503

  Zorick, Todd ^a,b   Sugar, Catherine A ^b   Hellemann, Gerhard ^b   Shoptaw, Steve ^b   London, Edythe D ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Antidepressants; Classification and regression trees; Craving; Methamphetamine; Sertraline

Indexed keywords

METHAMPHETAMINE; PLACEBO; SERTRALINE;

ADULT; ARTICLE; CLASSIFICATION; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ADDICTIVE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; SERTRALINE; TREATMENT OUTCOME;

EID: 80053572313     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.04.015     Document Type: Article

References (34)

1. Babor T.F., Hofmann M., Del Boca F.K., Hesselbrock V., Meyer R.E., Dolinsky Z.S., Rounsaville B. Types of alcoholics I. evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch. Gen. Psychiatry 1992, 49:599-608.
2. Batki S.L., Moon J., Delucchi K., Bradley M., Hersh D., Smolar S., Mengis M., Lefkowitz E., Sexe D., Morello L., Everhart T., Jones R.T., Jacob P. Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann. N. Y. Acad. Sci. 2000, 909:260-263.
3. Beck A.T., Steer R.A., Ball R., Ranieri W. Comparison of beck depression inventories-IA and -II in psychiatric outpatients. J. Pers. Assess. 1996, 67:588-597.
4. Breiman L., Friedman J.H., Olshen R.A., Stone C.J. Classification and Regression Trees 1983, Wadsworth, Belmont, CA.
5. Cruickshank C.C., Montebello M.E., Dyer K.R., Quigley A., Blaszczyk J., Tomkins S., Shand D. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008, 27:326-333.
6. Darke S., Ross J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 2000, 95:407-417.
7. Dean A.C., London E.D., Sugar C.A., Kitchen C.M., Swanson A.N., Heinzerling K.G., Kalechstein A.D., Shoptaw S. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009, 105:48-55.
8. Derogatis L.R., Melisaratos N. The brief symptom inventory: an introductory report. Psychol. Med. 1983, 13:595-605.
9. DiClemente C.C., Hughes S.O. Stages of change profiles in alcoholism treatment. J. Subst. Abuse 1990, 2:217-235.
10. Dundon W., Lynch K.G., Pettinati H.M., Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol. Clin. Exp. Res. 2004, 28:1065-1073.
11. Folstein M.F., Luria R. Reliability, validity, and clinical application of the visual analogue mood scale. Psychol. Med. 1973, 3:479-486.
12. Galloway G.P., Singleton E.G. How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: craving and ongoing methamphetamine use. Subst. Abuse 2009, 26:63-79. The Methamphetamine Treatment Project Corporate Authors.
13. Glasner-Edwards S., Marinelli-Casey P., Hillhouse M., Ang A., Mooney L.J., Rawson R. Depression among methamphetamine users: association with outcomes from the methamphetamine treatment project at 3-year follow-up. J. Nerv. Ment. Dis. 2009, 197:225-231. The Methamphetamine Treatment Project Corporate Authors.
14. Goldman L., Weinberg M., Weisberg M., Olshen R., Cook E.F., Sargent R.K., Lamas G.A., Dennis C., Wilson C., Deckelbaum L., Fineberg H., Stiratelli R.A. Computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N. Eng. J. Med. 1982, 307:588-596.
15. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology - Revised. DHEW Publication No. ADM 76-338, Rockville, MD, pp. 218-222.
16. Hartz D.T., Frederick-Osborne S.L., Galloway G.P. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001, 63:269-276.
17. Ilgen M.A., Downing K., Zivin K., Hoggatt K.J., Kim H.M., Ganoczy D., Austin K.L., McCarthy J.F., Patel J.M., Valenstein M. Exploratory data mining analysis identifying subgroups of patients with depression who are at high risk for suicide. J. Clin. Psychiatry 2009, 70:1495-1500.
18. Johnson B.A., Ait-Daoud N., Elkashef A.M., Smith E.V., Kahn R., Vocci F., Li S.H., Bloch D.A. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int. J. Neuropsychopharmacol. 2008, 11:1-14. Methamphetamine Study Group.
19. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynaud M., Batki S.L. Pharmacological approaches to methamphetamine dependence: a focused review. Br. J. Clin. Pharmacol. 2010, 69:578-592.
20. London E.D., Simon S.L., Berman S.M., Mandelkern M.A., Lichtman A.M., Bramen J., Shinn A.K., Miotto K., Learn J., Dong Y., Matochik J.A., Kurian V., Newton T., Woods R., Rawson R., Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2004, 61:73-84.
21. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index. J. Nerv. Ment. Dis. 1980, 168:26-33.
22. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320-1329.
23. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 1993, 6:1049-1056.
24. Moran J.L., Solomon P.J. Statistics in review. Part 2: generalised linear models, time-to-event and time-series analysis, evidence synthesis and clinical trials. Crit. Care Resusc. 2007, 9:187-197.
25. Munzar P., Baumann M.H., Shoaib M., Goldberg S.R. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology (Berl.) 1999, 141:287-296.
26. Nunes E.V., Levin F.R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004, 291:1887-1896.
27. Pettinati H.M. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J. Clin. Psychiatry 2001, 62:26-31.
28. Piasecki M.P., Steinagel G.M., Thienhaus O.J., Kohlenberg B.S. An exploratory study: the use of paroxetine for methamphetamine craving. J. Psychoactive Drugs 2002, 34:301-304.
29. R Development Core Team, 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
30. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Dang J., Roll J., Shapiro B., Rotheram-Fuller E., Ling W. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:12-18.
31. Shoptaw S.J., Kao U., Heinzerling K., Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst. Rev. 2009, 2. CD003021.
32. Takamatsu Y., Yamamoto H., Ogai Y., Hagino Y., Markou A., Ikeda K. Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann. N. Y. Acad. Sci. 2006, 1074:295-302.
33. United Nations Office on Drugs and Crime, 2009. World Drug Report, NY.
34. Zorick T., Nestor L., Miotto K., Sugar C., Hellemann G., Scanlon G., Rawson R., London E.D. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010, 105:1809-1818.